Management of Hyperglycemia Uncontrolled on Metformin

Introduction to Treatment Algorithm

The American Diabetes Association recommends adding basal insulin to metformin for patients with marked hyperglycemia or symptoms, as this is a highly effective next step 1, 2

For patients with severe hyperglycemia or symptoms, such as blood glucose ≥250 mg/dL or HbA1c ≥8.5% with symptoms, the American Diabetes Association suggests initiating basal insulin immediately while continuing metformin 3, 4
For patients with blood glucose >300-350 mg/dL or HbA1c ≥10-12%, the American Diabetes Association strongly considers insulin therapy from the outset, as this reflects more severe insulin deficiency 1, 5
For patients with catabolic features, such as weight loss or hypertriglyceridemia, or ketonuria, the American Diabetes Association mandates insulin therapy 1, 6

Long-acting insulin analogs, such as glargine or detemir, offer modest advantages over NPH insulin, including less overnight hypoglycemia and possibly slightly less weight gain, according to the American Diabetes Association 1, 2, 5
The American Diabetes Association notes that detemir typically requires higher average unit requirements than glargine 1, 2

If basal insulin alone does not achieve targets, the American Diabetes Association recommends progression to prandial insulin, adding rapid-acting insulin analogs before meals 1, 2, 5
The majority of type 2 diabetes patients can be successfully treated with basal insulin alone, with prandial insulin needed only when insulin secretory capacity progressively diminishes, according to the American Diabetes Association 2, 8

Proper education is imperative when initiating insulin, including glucose monitoring techniques and frequency, insulin injection technique and storage, recognition and treatment of hypoglycemia, and self-adjustment of insulin doses based on glucose trends, as recommended by the American Diabetes Association 1, 2, 5

The American Diabetes Association advises against using sliding scale insulin alone as primary therapy, as basal-bolus regimens are superior for glycemic control 7
The American Diabetes Association recommends avoiding metformin in patients with eGFR <30 mL/min/1.73 m², risk of lactic acidosis, or acute illness with hypoxia/shock, and monitoring for hypoglycemia risk when combining insulin with metformin 9
The American Diabetes Association suggests not delaying insulin initiation in symptomatic patients or those with very high glucose levels, as early intervention prevents further metabolic decompensation 1, 6